New 12-Month Preclinical Milestone in Regenerative Aesthetics
Conexeu completed a 12-month multi-tissue preclinical program in aesthetics. The program met its pre-defined objectives.
The Conexeu B.R.E.A.S.T.™ matrix is designed as an acellular, resorbable, bioregenerative scaffold, not as an implanted prosthesis. The design intent is to provide the initial structural architecture, and a matrix to enable biological support, needed to restore living, vascularized tissue.[3, 4, 7]
Conexeu’s tissue structure combines natural extracellular matrix proteins which allows cell migration, vasculogenesis, tissue integration and remodeling all supported by the patient’s own restorative processes.[1, 2, 3, 4, 5, 7]
The CXU™ platform introduces a potential new implantable device in soft tissue restoration, a resorbable and bioregenerative matrix engineered to guide the patient’s own cells towards the formation of new tissue.
How CXU Works
How CXU Works
Precision Structures
Printed for the specific geometry of defects, CXUTM 3D structures are intended to be pre-formed and implant-ready. Designed to fill large-volume tissue structures and maintain continuous contact from the moment of placement. 9,12
3D-printed to match the geometry of the defect, conforming to complex anatomical voids and large-volume tissue structures.2,3,4
Pre-engineered architecture is designed into the device, for volumetric correction and structural contouring with improved biological integration. 3,4,5
Designed to provide a smooth and uniform surface for maintaining continuous contact across the entire interface.3,4,5
How CXU Works
Precision Placement
Pre-formed and structurally stable at delivery, the construct provides immediate volume and a stable interface. Engineered to deliver the mechanical persistence required by large-volume tissue defects without depending on in-situ gelation. 9,12
Supports tissue integration without migration from the site of placement.4,5
Engineered for structural persistence and volume to sustain mechanical load.3,4,5
An ECM framework designed for uninterrupted matrix to tissue contact to support cell migration and new tissue in-growth 1,2,7
How CXU Works
Supporting Tissue Restoration
A controlled 3D architecture combined with a biomimetic ECM: a resorbable, temporary implant designed to be recognized, populated, and progressively remodeled by host tissue for tissue restoration. 1, 3, 4, 6, 10
In preclinical models, investigators report cell presence and infiltration within and at the CXU scaffold-tissue interface, consistent with a scaffold that supports host integration as part of normal tissue repair.3,4,5,7
Published in vivo studies report findings consistent with vascular ingrowth and remodeling in the presence of the scaffold, supporting the concept that CXU may serve as a structural framework allowing for tissue restoration.3,4,7
Preclinical evaluations report a reduced inflammatory profile in the presence of the CXU scaffold, consistent with a material that supports organized repair rather than a prolonged inflammatory phase.3,6,9,10
The scaffold is intended to be gradually resorbed through endogenous processes, leaving behind host tissue rather than a permanent foreign structure.3, 7, 9, 10, 11
Designed to provide both mechanical and biological support enabling the to body to ultimately remodel its own living tissue.*
A biomimetic extracellular matrix that is naturally derived and resorbable. Offering a more biologically supportive environment than fat grafting or implants alone.3,5,10
B.R.E.A.S.T™ Matrix is designed to transition from mechanical support to biological integration, with the host tissue progressively replacing the scaffold volume on a timeline aligned with tissue formation. 1,4,5,12
Designed to potentially lower complication and risk associated with incomplete closures and non-integrated interfaces. 6,9,10,12
Conexeu is not simply repairing tissue. We are building a new blueprint for regeneration, one that is disciplined, intentional and grounded in more than a decade of research.
Developed over 10 years at a leading Canadian University.
Conexeu owns the right, title, and interest to the patents worldwide.
Acta Biomaterialia, Advances in Wound Care, Biomedical Materials, Canadian Journal of Diabetes, Experimental Dermatology, Gels, Journal of Burn Care, Tissue Engineering, Transplantation
*All cited studies are preclinical. Findings have not been validated in human clinical trials and are not predictive of clinical outcomes.
